Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02664181
Title Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Decitabine + Nivolumab + Tetrahydrouridine

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Center for Cancer Research Bethesda Maryland 20892 United States Details
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio 44118 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field